Aditxt's Ignite Proteomics SPAC Merger Collapses as Parties Mutually Terminate Deal
ADTX is trading near its 52-week low of $0.004 (32% below the low).
Summary
Aditxt and Copley Acquisition Corp mutually terminated the June 10, 2026 SPAC merger for Aditxt's Ignite Proteomics subsidiary, effective October 9, 2026, with no further obligations between the parties.
Key Events · M&A and Partnerships · ADTX
-
SPAC Merger Terminated
Copley Acquisition Corp and Ignite Proteomics, LLC mutually terminated the June 10, 2026 Business Combination Agreement effective October 9, 2026, ending the planned take-public of Aditxt's subsidiary.
-
Ancillary Agreements Automatically Terminated
Seller Support Agreements, the Insider Letter Amendment, and Lock-Up Agreements all terminated concurrently with the BCA, and the parties exchanged mutual releases of claims.
-
Outside Date Passed Without Closing
The BCA's September 30, 2026 outside date, as automatically extended 30 days, expired without closing conditions being satisfied, prompting the mutual termination under Section 8.1(a).
-
Distress Context
The termination lands alongside a previously disclosed Nasdaq delisting notice and a Q1 2026 10-Q reporting substantial net losses and negative equity, leaving Aditxt to pursue alternative strategic transactions or financing.
Analysis · ADTX · Life Sciences
The SPAC merger that was supposed to take Aditxt's Ignite Proteomics subsidiary public is dead. The parties terminated the Business Combination Agreement by mutual consent on October 9, 2026, after the September 30 outside date passed without closing conditions being met. For a company already facing a Nasdaq delisting notice and severe financial distress, losing this exit path removes the most concrete route to a liquidity event for the subsidiary. Aditxt now has to find an alternative strategic transaction or financing, and the filing itself flags the risk that it may not be able to obtain additional financing or maintain sufficient liquidity to fund operations.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 39.9% of the 1148 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ADTX was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.8M. The 52-week trading range was $0.00 to $13,885.71. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.